Genfit Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Genfit de 54.7% y 26.5% por año respectivamente. Se prevé que el BPA crezca en un 90.3% al año. Se espera que la rentabilidad financiera sea de 8.2% en 3 años.

Información clave

54.7%

Tasa de crecimiento de los beneficios

90.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	29.3%
Tasa de crecimiento de los ingresos	26.5%
Rentabilidad financiera futura	8.2%
Cobertura de analistas	Low
Última actualización	08 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:GNFT - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	105	38	N/A	N/A	4
12/31/2025	49	-21	17	17	5
12/31/2024	90	15	3	3	4
12/31/2023	34	-29	-58	-55	N/A
9/30/2023	32	-32	-55	-53	N/A
6/30/2023	29	-34	-52	-50	N/A
3/31/2023	28	-29	-62	-61	N/A
12/31/2022	26	-24	-73	-73	N/A
9/30/2022	60	12	4	4	N/A
6/30/2022	94	48	80	80	N/A
3/31/2022	90	58	90	90	N/A
12/31/2021	85	67	99	100	N/A
9/30/2021	46	14	10	11	N/A
6/30/2021	6	-39	-79	-79	N/A
3/31/2021	7	-70	-88	-88	N/A
12/31/2020	9	-101	-97	-96	N/A
9/30/2020	24	-84	-73	-71	N/A
6/30/2020	39	-67	-49	-46	N/A
3/31/2020	39	-66	-49	-47	N/A
12/31/2019	39	-65	-50	-48	N/A
9/30/2019	23	-80	-62	-60	N/A
6/30/2019	8	-94	-73	-71	N/A
3/31/2019	8	-87	-66	-64	N/A
12/31/2018	7	-80	-59	-56	N/A
9/30/2018	7	-75	N/A	N/A	N/A
6/30/2018	7	-70	-58	-56	N/A
3/31/2018	7	-63	-55	-53	N/A
12/31/2017	7	-56	-53	-50	N/A
9/30/2017	7	-50	N/A	N/A	N/A
6/30/2017	8	-44	N/A	-40	N/A
3/31/2017	7	-39	N/A	-34	N/A
12/31/2016	7	-34	N/A	-27	N/A
9/30/2016	6	-27	N/A	-23	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-19	N/A	-16	N/A
12/31/2015	4	-17	N/A	-15	N/A
9/30/2015	5	-17	N/A	-17	N/A
6/30/2015	5	-17	N/A	-19	N/A
3/31/2015	6	-17	N/A	-17	N/A
12/31/2014	7	-17	N/A	-15	N/A
9/30/2014	7	-15	N/A	-15	N/A
6/30/2014	7	-14	N/A	-14	N/A
3/31/2014	6	-13	N/A	-11	N/A
12/31/2013	6	-13	N/A	-9	N/A
9/30/2013	6	-11	N/A	-8	N/A
6/30/2013	6	-9	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que GNFT sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que GNFT sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que GNFT sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (26.5% al año) de GNFT crezcan más rápidamente que los del mercado French (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (26.5% al año) de GNFT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GNFT sea baja dentro de 3 años (8.2%).

Genfit Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus EPS estimates increase by 291%

Price target increased by 9.4% to €9.72

Consensus revenue estimates decrease by 21%

Price target increased by 9.4% to €9.70

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.76

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Is Genfit (EPA:GNFT) A Risky Investment?

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Analysts update estimates

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.86

Previsiones de crecimiento de beneficios e ingresos